Navigation Links
BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes
Date:10/30/2009

SAN DIEGO and INDIANAPOLIS, Oct. 30, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for BYETTA® (exenatide) injection. BYETTA is now approved for use as a stand-alone medication (monotherapy) along with diet and exercise to improve glycemic control in adults with type 2 diabetes. Previously, it was approved for use only in patients who were also taking other common diabetes medications and had not achieved adequate glycemic control.

"The expanded indication gives physicians the option to prescribe BYETTA as a first-line treatment, increasing the number of patients who may benefit from the medication and providing an opportunity to treat patients with BYETTA earlier in the disease," said Orville G. Kolterman, M.D., senior vice president of research and development, Amylin Pharmaceuticals. "Type 2 diabetes is a complex disease, so it is essential that healthcare professionals and their patients have a wide array of treatments that can effectively control blood glucose levels."

The approval of BYETTA as a monotherapy treatment was based on a clinical study of patients with type 2 diabetes who were unable to achieve glycemic control through diet and exercise alone. Study findings showed that patients treated with 5 mcg or 10 mcg of BYETTA as monotherapy reduced their A1C, a measure of average blood sugar over three months, by 0.7 percentage points and 0.9 percentage points, respectively, and lost 6.0 pounds and 6.4 pounds, respectively. Results of this study were published in Clinical Therapeutics in August 2008.(i)

Among treatment-emerg
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA
2. Surveyed Experts Indicate That Byetta LAR and Victoza Have Advantages Over Actos in the Treatment of Type 2 Diabetes
3. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
4. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
5. Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction
6. Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
7. Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer
8. EVICEL(TM) Fibrin Sealant (Human) Approved for General Hemostasis in Surgery
9. Clexane(R)/Lovenox(R) Approved in Japan
10. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
11. Center for Molecular Medicine Among First to Offer New FDA-Approved Test to Aid in Treatment of Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Feb. 26, 2015 The healthcare landscape is rapidly ... Frost & Sullivan will host its 20 th ... , March 8 to 10, at the Hilton San Diego ... This event is a platform for global ... discuss industry disruptions and how to succeed in an uncertain ...
(Date:2/26/2015)... Frederick, MD (PRWEB) February 26, 2015 ... solutions provider, released FreezerPro® version 6.2 – the latest ... The FreezerPro® reputation is that of a quick and ... related work. With the latest version, RURO engineering has ... on import to move large amounts of sample records. ...
(Date:2/26/2015)... ANGELES , Feb. 26, 2015 Tauriga ... life sciences company with interests in the natural wellness ... technology, announced today that its products will be featured ... Roth Capital Partners, 27 th Annual Growth Stock ... Carlton, located at 1 Ritz Carlton Drive, ...
(Date:2/26/2015)... On Wednesday, February 25, Peggy Lillis Foundation, ... difficile (C. diff) awareness movement, lauded the release ... Centers for Disease Control & Prevention . The study ... infections among Americans in a single year, including more ... study also estimates that 29,000 patients died within 30 ...
Breaking Biology Technology:Embrace the Future of Medical Technologies with Frost & Sullivan 2Embrace the Future of Medical Technologies with Frost & Sullivan 3RURO Releases FreezerPro® version 6.2 2SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 2SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 3SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 4Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 2Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 3Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 4
... AutoImmune Inc. (OTC Bulletin Board: AIMM) today reported a net loss ... three months ended June 30, 2009, compared with a net loss ... three months ended June 30, 2008. For the six months ended ... share basic and diluted, compared with net loss of $193,000, or ...
... and Semen Sexing Technology achieves, milestone, , ... ended June 30, 2009, Microbix Biosystems Inc. (TSX:MBX) announced strong ... had a small sales retraction that was related to timing ... continued growth in sales. , "The 22% sales growth achieved ...
... , ROCKVILLE, Md., Aug. 6 Novavax, ... of Frederick W. Driscoll as Vice President, Chief Financial Officer ... Singhvi, Novavax,s President and Chief Executive Officer. , , ... and President and Chief Executive Officer of Genelabs Technologies, Inc. ...
Cached Biology Technology:AutoImmune Inc. Reports 2009 Second Quarter Financial Results 2AutoImmune Inc. Reports 2009 Second Quarter Financial Results 3AutoImmune Inc. Reports 2009 Second Quarter Financial Results 4AutoImmune Inc. Reports 2009 Second Quarter Financial Results 5Microbix Sales Grow 22% For Nine Months 2Microbix Sales Grow 22% For Nine Months 3Microbix Sales Grow 22% For Nine Months 4Microbix Sales Grow 22% For Nine Months 5Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer 2
(Date:2/24/2015)... , Feb. 24, 2015 This report analyzes the ... the following Segments: Face Biometrics, and Voice Biometrics. The report provides ... Japan , Europe , ... Africa , and Latin America ... through 2020. Also, a seven-year historic analysis is provided for these ...
(Date:2/19/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/kx9zp8/military ) ... Electro-Optical / Infrared Systems Market by Type, by ... to 2020" report to their offering. ... expected to reach $16.35 billion by 2020, to ... report segments the military electro-optical/infrared systems market on ...
(Date:2/12/2015)... 2015   MedNet Solutions , a global ... management systems, has recently bolstered its ... iMedNet as the eClinical solution ... healthcare consultants.  Building on the Program,s existing benefits ... numerous co-marketing opportunities), MedNet,s new and improved program ...
Breaking Biology News(10 mins):World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2
... Neurotechnology , a provider of high-precision biometric ... MegaMatcher 4.0 , a multi-biometric software development kit ... biometrics in a single, high-performance SDK that requires ... palmprint technology along with the latest versions of ...
... for making one species into two requires time and ... or something else that discourages gene flow between the ... Texas wildflowers that share meadows and roadside ditches, color-coding ... Robin Hopkins has found the first evidence of a ...
... The first commercial crop of a new mandarin variety ... will be harvested beginning later this month. The ... mutation of W. Murcott mandarin. Originally from Morocco, W. ... and tangy-sweet flavor traits shared by the Tango. ...
Cached Biology News:New MegaMatcher 4.0 from Neurotechnology Integrates Fingerprint, Iris, Facial and Palmprint Biometrics In One High-Performance SDK 2New MegaMatcher 4.0 from Neurotechnology Integrates Fingerprint, Iris, Facial and Palmprint Biometrics In One High-Performance SDK 3Wildflower colors tell butterflies how to do their jobs 2Tango mandarins to appear this month in produce aisles 2Tango mandarins to appear this month in produce aisles 3
QPRT Antibody...
Protein Marker Detection Pack contains biotinylate...
Mouse monoclonal [4C4] to Y14 ( Abpromise for all tested applications). entrezGeneID: 9939 SwissProtID: Q9Y5S9...
JMJD2B Antibody...
Biology Products: